MoonLake Immunotherapeutics 因谎称其药物的表现优于竞争对手而面临诉讼，导致股价暴跌 90%，因为试验结果显示它没有这样做。 MoonLake Immunotherapeutics faces a lawsuit for falsely claiming its drug outperformed rivals, causing stock to crash 90% after trial results revealed it didn’t.

2024年3月10日至2025年9月29日,针对MoonLake Immuntheretics(MLTX)提起了证券集团诉讼,指控该公司对其毒品 sonelokimab(SLK)提出虚假或误导性指控,高估了它相对于竞争者的效力。 A securities class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) alleging the company made false or misleading claims about its drug sonelokimab (SLK) from March 10, 2024, to September 29, 2025, overstating its efficacy over competitors. 当第3阶段试验结果于2025年9月28日发布时,该药物未能证明具有竞争效益,导致库存价值下降近90%。 When Phase 3 trial results were released on September 28, 2025, the drug failed to demonstrate competitive benefits, triggering a nearly 90% drop in stock value. 在类别期间购买MLTX股票的投资者可能有资格参加诉讼,2025年12月15日是提出索赔的最后期限。 Investors who bought MLTX stock during the class period may qualify to join the lawsuit, with a December 15, 2025, deadline to file claims. 此案由专门从事证券诉讼的律师事务所处理,不需任何费用参与。 The case is being handled by law firms specializing in securities litigation, with no cost to participate.